GWPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GWPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). GW Pharmaceuticals's Cash per Share for the quarter that ended in Mar. 2021 was $14.53.
The historical data trend for GW Pharmaceuticals's Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GW Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Sep11 | Sep12 | Sep13 | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Dec19 | Dec20 | |||||||||||
Cash per Share | Get a 7-Day Free Trial | 19.38 | 12.70 | 12.52 | 17.36 | 15.57 |
GW Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
Cash per Share | Get a 7-Day Free Trial | 16.14 | 15.34 | 15.41 | 15.57 | 14.53 |
This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.
GW Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2020 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 486.752 | / | 31.3 | |
= | 15.57 |
GW Pharmaceuticals's Cash per Share for the quarter that ended in Mar. 2021 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 458.101 | / | 31.5 | |
= | 14.53 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GW Pharmaceuticals (NAS:GWPH) Cash per Share Explanation
Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.
Thank you for viewing the detailed overview of GW Pharmaceuticals's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Douglas B. Snyder | officer: Chief Legal Officer | SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB249BZ |
Volker Knappertz | officer: Chief Medical Officer | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ |
Cabot Brown | director | SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ |
Adam D. George | officer: Secretary | SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ |
Guy Geoffrey W Dr | director, officer: Executive Chairman | ETHICAL HOLDINGS PLC CORPUS CHRISTI HOUSE 9 WEST STREET GODMANCHESTER CAMBRIDGESHIRE PE18 A1 |
Christopher J. Tovey | officer: Chief Operating Officer | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ |
Justin D. Gover | director, officer: Chief Executive Officer | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ |
David W Gryska | director | 749 N MARY AVE, SUNNYVALE CA 94085 |
James Noble | director | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Alicia Secor | director | 33 HAYDEN AVE., LEXINGTON MA 02421 |
Darren S Cline | officer: U.S. Chief Commercial Officer | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Catherine J Mackey | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
William A. Waldegrave | director | SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ |
Scott M. Giacobello | officer: Chief Financial Officer | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ |
Julian S Gangolli | officer: President, North America | 4955 BASELINE AVENUE, SANTA YNEZ CA 93460 |
From GuruFocus
By PRNewswire PRNewswire • 02-04-2021
By PRNewswire PRNewswire • 02-10-2021
By GuruFocus Research GuruFocus Editor • 11-18-2020
By Marketwired Marketwired • 04-29-2021
By PRNewswire PRNewswire • 02-25-2021
By GuruFocus Research GuruFocus Editor • 12-03-2020
By Marketwired Marketwired • 04-23-2021
By Marketwired Marketwired • 02-03-2021
By Marketwired Marketwired • 01-05-2021
By Marketwired Marketwired • 11-30-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.